research 17β-Estradiol and ICI-182780 regulate the hair follicle cycle in mice through an estrogen receptor-α pathway
Estradiol stops hair growth in mice, but an antagonist can reverse this effect.
Search
for
Sort by
Research
510-540 / 1000+ results
research Drug reaction with eosinophilia and systemic symptoms and severe involvement of digestive tract: description of two cases
Severe digestive issues in DRESS need early endoscopy for better treatment.
research LB822 Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in breast cancer cells
Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
research PCOS and Obesity: Contraception Challenges
Low-dose ethinyl estradiol and LNG-IUD are safer contraception options for obese women with PCOS.
research Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.
research Amphiregulin in Fibrotic Diseases and Cancer
Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.
research Oral Isotretinoin in HIV-Positive Women with Acne: Report of Three Cases
Isotretinoin effectively treated severe acne in HIV-positive women, with improved skin and CD4 counts, but some experienced side effects like skin dryness and hair loss.
research Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain
Gestrinone pellets may help reduce pelvic pain in endometriosis safely.
research Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
research Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
research Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
research Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH
GnRH treatment can reduce breast cancer cell invasion.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research Litigation associated with 5-alpha-reductase-inhibitor use: A Canadian legal database review.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
research New drugs: Iobenguane sulfate
Lifestyle changes are more effective than metformin in reducing type 2 diabetes risk in women with PCOS.
research Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception
Certain hormone medications can treat symptoms like acne and unwanted hair, regulate periods, and prevent pregnancy in women and teenage girls.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
research Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
research Pilot Evaluation of the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Women with Hair Loss
Xtressé™ gummies are safe and may help improve hair in women with non-scarring hair loss.
research Circulating and/or cutaneous irisin resistance: A novel link among androgenetic alopecia, comorbid metabolic syndrome and cardiovascular risks
Androgenetic alopecia is linked to higher cardiovascular and metabolic risks, possibly due to irisin resistance.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.